Abstract Library

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#3565 Grade 3 neuroendocrine neoplasms – Real life experience and prognostic biomarkers

Introduction: Grade 3 neuroendocrine neoplasms (G3 NEN) are a heterogeneous group, including well differentiated tumors (NET) and poorly differentiated carcinomas (NEC), whose identification can be challenging. Accessible prognostic tools are needed to individualize treatment. Data suggests neutrophil/lymphocyte ratios (NLR) and systemic inflammatory index (SII) have prognostic value in NEN.

Conference:

Presenting Author: Rebordão Pires M

Authors: Rebordão Pires M, Monteiro J, Amorim Costa C, Caetano A, Elvas A,

Keywords: Grade 3 neuroendocrine neoplasm, NEC, NET, Neutrophil to lymphocyte ratio, Systemic Inflammatory Index, Ki67, Prognostic biomarker,

#3523 NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site

Introduction: G3 NENs are aggressive tumors with limited treatment options. Prognosis is rather poor even with best available platinum-based CT (OS of 11m).

Conference:

Presenting Author:

Authors: Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teulé A,

Keywords: Grade 3 Neuroendocrine Neoplasm, nivolumab, gastroenteropancreatic,

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs

Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sun T

Authors: Sun T, Van Hummelen P, Martin B, Xia C, Zhao L,

Keywords: grade 3, high grade, neuroendocrine carcinoma, whole exome sequencing, rna-seq, transcriptomics, copy number analysis, sequencing, genomics, poorly differentiated,